Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Hutarew

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Thoracic Cancer|January 15, 2016
ROS1 mutation and treatment with crizotinib in a 30-year old Caucasian woman with stage IV non-small cell lung cancer/adenocarcinoma and complete remissionMarkus Blaukovitsch, Johann Hofer, Georg Hutarew, et al.
Urology|April 3, 2003
Evaluation of transition zone and lateral sextant biopsies for prostate cancer detection after initial sextant biopsyKlaus G Fink, Georg Hutarew, Brigitte Esterbauer, et al.
Oncotarget|April 18, 2018
Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancerFlorian Huemer, Gabriel Rinnerthaler, Theresa Westphal, et al.
Cancers|July 14, 2023
Dissecting the Methylomes of <i>EGFR</i>-Amplified Glioblastoma Reveals Altered DNA Replication and Packaging, and Chromatin and Gene Silencing PathwaysTheo F J Kraus, Celina K Langwieder, Dorothee Hölzl, et al.
Biomedicines|April 23, 2022
<i>EGFR</i> Amplification Is a Phenomenon of <i>IDH</i> Wildtype and <i>TERT</i> Mutated High-Grade Glioma: An Integrated Analysis Using Fluorescence In Situ Hybridization and DNA Methylome ProfilingDorothee Hölzl, Georg Hutarew, Barbara Zellinger, et al.
Journal of Cancer Research and Clinical Oncology|May 8, 2021
Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade gliomaDorothee Hölzl, Georg Hutarew, Barbara Zellinger, et al.
Journal of Cancer|December 24, 2025
Loss of <i>CDKN2A/B</i> is a Hallmark of RTK II GlioblastomasCelina K Langwieder, Dorothee Hölzl, Georg Hutarew, et al.
Journal of Clinical Medicine|July 13, 2019
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 BlockadeFlorian Huemer, David Lang, Theresa Westphal, et al.
BMC Cancer|October 18, 2015
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancerThomas Melchardt, Clemens Hufnagl, Teresa Magnes, et al.
Virchows Archiv : an International Journal of Pathology|November 23, 2023
HER2 copy number determination in breast cancer using the highly sensitive droplet digital PCR methodBeate Alinger-Scharinger, Cornelia Kronberger, Georg Hutarew, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Thoracic Cancer|January 15, 2016
ROS1 mutation and treatment with crizotinib in a 30-year old Caucasian woman with stage IV non-small cell lung cancer/adenocarcinoma and complete remissionMarkus Blaukovitsch, Johann Hofer, Georg Hutarew, et al.
Urology|April 3, 2003
Evaluation of transition zone and lateral sextant biopsies for prostate cancer detection after initial sextant biopsyKlaus G Fink, Georg Hutarew, Brigitte Esterbauer, et al.
Oncotarget|April 18, 2018
Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancerFlorian Huemer, Gabriel Rinnerthaler, Theresa Westphal, et al.
Cancers|July 14, 2023
Dissecting the Methylomes of <i>EGFR</i>-Amplified Glioblastoma Reveals Altered DNA Replication and Packaging, and Chromatin and Gene Silencing PathwaysTheo F J Kraus, Celina K Langwieder, Dorothee Hölzl, et al.
Biomedicines|April 23, 2022
<i>EGFR</i> Amplification Is a Phenomenon of <i>IDH</i> Wildtype and <i>TERT</i> Mutated High-Grade Glioma: An Integrated Analysis Using Fluorescence In Situ Hybridization and DNA Methylome ProfilingDorothee Hölzl, Georg Hutarew, Barbara Zellinger, et al.
Journal of Cancer Research and Clinical Oncology|May 8, 2021
Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade gliomaDorothee Hölzl, Georg Hutarew, Barbara Zellinger, et al.
Journal of Cancer|December 24, 2025
Loss of <i>CDKN2A/B</i> is a Hallmark of RTK II GlioblastomasCelina K Langwieder, Dorothee Hölzl, Georg Hutarew, et al.
Journal of Clinical Medicine|July 13, 2019
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 BlockadeFlorian Huemer, David Lang, Theresa Westphal, et al.
BMC Cancer|October 18, 2015
CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancerThomas Melchardt, Clemens Hufnagl, Teresa Magnes, et al.
Virchows Archiv : an International Journal of Pathology|November 23, 2023
HER2 copy number determination in breast cancer using the highly sensitive droplet digital PCR methodBeate Alinger-Scharinger, Cornelia Kronberger, Georg Hutarew, et al.
Pageof 3